• News Ticker alerts

Anadys Pharmaceuticals, which specializes in developing hepatitis C treatments, announced this morning (Oct. 17) that it will be acquired by the pharmaceutical giant Roche for $230 million, or $3.70 a share -- a premium of almost 260% over Friday's close. So today, Anadys stock leapt 250.96% to $3.65. Its board has approved the deal.

  • News Ticker alerts

Comments

Sign in to comment